100th patient enrolled in US study ahead of schedule

• Epiminder has enrolled the 100th participant in DETECT, its prospective, randomised, controlled, blinded, multi-centre US study of the Minder System, bringing the study to nearly half of its planned enrolment of up to 210 participants. • The milestone was achieved ahead of the Company’s November target, and reflects strong enrolment momentum across 22 world-class epilepsy centres in the United S